CO2019011547A2 - Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol - Google Patents

Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol

Info

Publication number
CO2019011547A2
CO2019011547A2 CONC2019/0011547A CO2019011547A CO2019011547A2 CO 2019011547 A2 CO2019011547 A2 CO 2019011547A2 CO 2019011547 A CO2019011547 A CO 2019011547A CO 2019011547 A2 CO2019011547 A2 CO 2019011547A2
Authority
CO
Colombia
Prior art keywords
pyrazol
pyridin
hydrochloride
propyl
phenyl
Prior art date
Application number
CONC2019/0011547A
Other languages
English (en)
Inventor
Sung Hwan Moon
Soo Jin Lee
Sung Chan Lee
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CO2019011547A2 publication Critical patent/CO2019011547A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con un clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1H-pirazol-5-ol cristalino novedoso, un método para preparar el compuesto, y una composición farmacéutica que contiene el compuesto como un ingrediente activo.
CONC2019/0011547A 2017-04-20 2019-10-17 Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol CO2019011547A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170050924A KR101856444B1 (ko) 2017-04-20 2017-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
PCT/KR2018/004604 WO2018194416A1 (ko) 2017-04-20 2018-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물

Publications (1)

Publication Number Publication Date
CO2019011547A2 true CO2019011547A2 (es) 2020-02-18

Family

ID=62184173

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011547A CO2019011547A2 (es) 2017-04-20 2019-10-17 Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol

Country Status (15)

Country Link
US (1) US11174240B2 (es)
EP (1) EP3613733B1 (es)
JP (1) JP6982097B2 (es)
KR (1) KR101856444B1 (es)
CN (1) CN110678455B (es)
AU (1) AU2018256259B2 (es)
BR (1) BR112019022002A2 (es)
CA (1) CA3060046C (es)
CL (1) CL2019002986A1 (es)
CO (1) CO2019011547A2 (es)
ES (1) ES2924798T3 (es)
MX (1) MX2019012454A (es)
PL (1) PL3613733T3 (es)
RU (2) RU2754255C2 (es)
WO (1) WO2018194416A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
CN114746079A (zh) * 2019-11-21 2022-07-12 三进制药株式会社 用于预防或治疗眼部疾病的滴眼剂组合物
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
US20230201179A1 (en) * 2020-04-08 2023-06-29 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
CN115427039A (zh) * 2020-04-13 2022-12-02 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179282C (no) * 1991-01-18 1996-09-11 Rhone Poulenc Agrochimie Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20120098489A (ko) 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물
KR20120098462A (ko) 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
TW201603849A (zh) 2014-07-01 2016-02-01 賽諾菲公司 響片配置及其藥物輸送裝置

Also Published As

Publication number Publication date
RU2021116820A (ru) 2021-06-22
RU2754255C2 (ru) 2021-08-31
CN110678455B (zh) 2022-08-16
BR112019022002A2 (pt) 2020-05-12
CL2019002986A1 (es) 2020-01-24
CA3060046A1 (en) 2018-10-25
CN110678455A (zh) 2020-01-10
AU2018256259B2 (en) 2020-06-18
KR101856444B1 (ko) 2018-05-10
RU2019132946A (ru) 2021-04-19
RU2019132946A3 (es) 2021-04-19
PL3613733T3 (pl) 2022-09-26
MX2019012454A (es) 2019-12-19
US20210122726A1 (en) 2021-04-29
CA3060046C (en) 2021-08-31
AU2018256259A1 (en) 2019-11-07
EP3613733A4 (en) 2020-11-18
US11174240B2 (en) 2021-11-16
ES2924798T3 (es) 2022-10-11
JP2020517661A (ja) 2020-06-18
WO2018194416A1 (ko) 2018-10-25
JP6982097B2 (ja) 2021-12-17
EP3613733B1 (en) 2022-07-20
EP3613733A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
EA202090732A1 (ru) Составы для трансдермального введения
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
EA201691741A1 (ru) Фармацевтическая композиция
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
BR112017004595A2 (pt) composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза